Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 1;100(7):425-431.
doi: 10.1097/OPX.0000000000002040. Epub 2023 Jun 24.

Accommodation in Children after 4.7 Years of Multifocal Contact Lens Wear in the BLINK Study Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

Accommodation in Children after 4.7 Years of Multifocal Contact Lens Wear in the BLINK Study Randomized Clinical Trial

Moriah A Chandler et al. Optom Vis Sci. .

Abstract

Significance: When worn for myopia control in children, soft multifocal contact lenses with a +2.50 D add reduced the accommodative response over a 3-year period, but wearing them for more than 4 years did not affect accommodative amplitudes, lag, or facility.

Purpose: This study aimed to compare the accommodative response to a 3D stimulus between single-vision, +1.50-D add, and +2.50-D add multifocal contact lens wearers during 3 years of contact lens wear and then to compare accommodative amplitude, lag, and facility between the three groups after an average of 4.7 years of wear.

Methods: Bifocal Lenses In Nearsighted Kids study participants aged 7 to 11 years old were randomly assigned to wear single-vision, +1.50-D add, or +2.50-D add soft contact lenses (CooperVision, Pleasanton, CA). The accommodative response to a 3D stimulus was measured at baseline and annually for 3 years. After 4.7 years, we measured objective accommodative amplitudes, lead/lag, and binocular facility with ±2.00-D flippers. We compared the three accommodative measures using multivariate analysis of variance (MANOVA), adjusting for clinic site, sex, and age group (7 to 9 or 10 to 11 years).

Results: The +2.50-D add contact lens wearers exhibited lower accommodative response than the single-vision contact lens wearers for 3 years, but the +1.50-D add contact lens wearers exhibited only lower accommodative response than did the single-vision contact lens wearers for 2 years. After adjustment for clinic site, sex, and age group, there were no statistically significant or clinically meaningful differences between the three treatment groups for accommodative amplitude (MANOVA, P = .49), accommodative lag (MANOVA, P = .41), or accommodative facility (MANOVA, P = .87) after an average of 4.7 years of contact lens wear.

Conclusions: Almost 5 years of multifocal contact lens wear did not affect the accommodative amplitude, lag, or facility of children.

Trial registration: ClinicalTrials.gov NCT02255474 NCT04080128.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: One author listed reports a financial conflict of interest (DOM). The sponsor provided financial and material support, but had no role in the study design, conduct, analysis and interpretation, or writing of the report.

Figures

Figure 1.
Figure 1.
Retention of BLINK Study participants randomly assigned to wear single vision, +1.50 D add, or +2.50 D add contact lenses who had their accommodation measured when they enrolled in the BLINK2 Study. The gray box indicates time of participation in the BLINK Study; outside of the gray box indicates enrollment in the BLINK2 Study.
Figure 2.
Figure 2.
Mean ± 95% confidence interval of the accommodative response to a 3 D stimulus for each treatment group after wearing the assigned contact lenses for two weeks, 1 year, 2 years, and 3 years.

References

    1. Wolffsohn JS, Calossi A, Cho P, et al. Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice – 2019 Update. Contact Lens Anter Eye 2020;43:9–17. - PubMed
    1. Lee JJ, Fang PC, Yang IH, et al. Prevention of Myopia Progression with 0.05% Atropine Solution. J Ocul Pharmacol Ther 2006;22:41–6. - PubMed
    1. Chia A, Chua WH, Cheung YB, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012;119:347–54. - PubMed
    1. Clark TY, Clark RA. Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. J Ocul Pharmacol Ther 2015;31:541–5. - PubMed
    1. Larkin GL, Tahir A, Epley KD, et al. Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample across Three US Sites. Ophthalmol Ther 2019;8:589–98. - PMC - PubMed

Publication types

Associated data